Stock RIV CANOPY RIVERS J SV A
Add to a list
To use this feature you must be a member
Log inSign up

Financials CANOPY RIVERS J SV A Toronto S.E.

Equities

RIV

CA7680141024

Pharmaceuticals

End-of-day quote Toronto S.E.
Other stock markets
 06:00:00 2021-09-21 pm EDT 		5-day change 1st Jan Change
1.52 CAD +1.67% Intraday chart for CANOPY RIVERS J SV A -7.41% +28.21%
Feb. 14 RIV Capital Reports Opening of Adult-Use Dispensary in White Plains, New York, by Etain MT
2023 RIV Capital Up 13.6% After Reporting Approval for Etain to Start Sales to Adult-Use Market in New YorK MT

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023
Capitalization 1 525.5 121 262.2 165.2 12.02
Enterprise Value (EV) 2 421.5 74.96 134.8 -132.4 24.47
P/E ratio 141 x -2.9 x -2.57 x -3.13 x -0.08 x
Yield - - - - -
Capitalization / Revenue 13.7 x 9.92 x 19.5 x 87.1 x 1.77 x
EV / Revenue 11 x 6.15 x 10 x -69.8 x 3.6 x
EV / EBITDA - -10,181,799 x -2,189,545 x 10,170,896 x -1,463,204 x
EV / FCF 16,445,388 x -14,162,803 x -15,754,541 x 3,290,009 x -958,684 x
FCF Yield 0% -0% -0% 0% -0%
Price to Book 1.29 x 0.41 x 0.85 x 0.5 x 0.11 x
Nbr of stocks (in thousands) 186,516 189,305 141,454 142,445 135,408
Reference price 3 2.817 0.6391 1.854 1.160 0.0887
Announcement Date 7/16/19 6/3/20 6/3/21 6/13/22 6/14/23
1USD in Million2CAD in Million3USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 54.78 38.48 12.19 13.43 1.896 6.807
EBITDA - - -7.362 -61.56 -13.01 -16.72
EBIT 1 46.81 8.027 -7.381 -61.59 -13.08 -16.9
Operating Margin 85.45% 20.86% -60.54% -458.6% -690.08% -248.33%
Earnings before Tax (EBT) 1 46.74 8.343 -40.62 -152.4 -65.2 -182.2
Net income 1 39.67 3.918 -40.57 -133.9 -52.73 -179.3
Net margin 72.42% 10.18% -332.75% -996.87% -2,781.17% -2,633.45%
EPS 2 0.3927 0.0200 -0.2200 -0.7200 -0.3702 -1.092
Free Cash Flow - 25.63 -5.293 -8.555 -40.23 -25.53
FCF margin - 66.61% -43.41% -63.7% -2,121.95% -375.01%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - 654.16% - - - -
Dividend per Share - - - - - -
Announcement Date 8/21/18 7/16/19 6/3/20 6/3/21 6/13/22 6/14/23
1CAD in Million2CAD
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - 12.5
Net Cash position 1 45.8 104 46 127 298 -
Leverage (Debt/EBITDA) - - - - - -0.7448 x
Free Cash Flow - 25.6 -5.29 -8.56 -40.2 -25.5
ROE (net income / shareholders' equity) - 1.31% -11.5% -43.9% -16.4% -96%
ROA (Net income/ Total Assets) - 1.6% -1.28% -12.1% -2.06% -3.36%
Assets 1 - 245.4 3,164 1,106 2,557 5,328
Book Value Per Share 2 1.470 2.180 1.580 2.190 2.320 0.8000
Cash Flow per Share 2 0.3500 0.5600 0.2500 0.9000 2.790 0.5700
Capex - - - - - 4.55
Capex / Sales - - - - - 66.87%
Announcement Date 8/21/18 7/16/19 6/3/20 6/3/21 6/13/22 6/14/23
1CAD in Million2CAD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Alternative Medicine

1st Jan change Capi.
DONG-E-E-JIAO CO.,LTD. Stock Dong-E-E-Jiao Co.,Ltd.
+35.04% 5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD. Stock Shijiazhuang Yiling Pharmaceutical Co., Ltd.
-15.13% 4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD Stock Tasly Pharmaceutical Group Co., Ltd
-9.75% 3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Stock Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
+2.14% 3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. Stock Shandong Buchang Pharmaceuticals Co., Ltd.
-6.82% 2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD. Stock Henan Lingrui Pharmaceutical Co., Ltd.
+47.87% 1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD. Stock GuangYuYuan Chinese Herbal Medicine Co., Ltd.
-7.89% 1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD. Stock Tibet Cheezheng Tibetan Medicine Co., Ltd.
+0.09% 1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD Stock Tianjin Chase Sun Pharmaceutical Co.,Ltd
-12.97% 1.53B
Alternative Medicine
  1. Stock Market
  2. Equities
  3. RIV Stock
  4. RIV Stock
  5. Financials CANOPY RIVERS J SV A